Aims: Drug disposition in children may vary from adults due to age-related variation in drug metabolism. Microdose studies present an innovation to study pharmacokinetics (PK) in paediatrics; however, they should be used only when the PK is dose linear. We aimed to assess dose linearity of a [ 14 C]midazolam microdose, by comparing the PK of an intravenous (IV) microtracer (a microdose given simultaneously with a therapeutic midazolam dose), with the PK of a single isolated microdose. Methods: Preterm to 2-year-old infants admitted to the intensive care unit received [ 14 C]midazolam IV as a microtracer or microdose, followed by dense blood sampling up to 36 hours. Plasma concentrations of [ 14 C]midazolam and [ 14 C]1-hydroxy-midazolam were determined by accelerator mass spectrometry. Noncompartmental PK analysis was performed and a population PK model was developed. Results: Of 15 infants (median gestational age 39.4 [range 23.9-41.4] weeks, postnatal age 11.4 [0.6-49.1] weeks), 6 received a microtracer and 9 a microdose of [ 14 C] midazolam (111 Bq kg −1 ; 37.6 ng kg −1 ). In a 2-compartment PK model, bodyweight was the most significant covariate for volume of distribution. There was no statistically significant difference in any PK parameter between the microdose and microtracer, nor in the area under curve ratio [ 14 C]1-OH-midazolam/[ 14 C]midazolam, showing the PK of midazolam to be linear within the range of the therapeutic and microdoses. Conclusion: Our data support the dose linearity of the PK of an IV [ 14 C]midazolam microdose in children. Hence, a [ 14 C]midazolam microdosing approach may be used as an alternative to a therapeutic dose of midazolam to study developmental changes in hepatic CYP3A activity in young children.
arity may occur for example, when a therapeutic dose saturates drug metabolism pathways, plasma protein binding and/or active transporters, which may result in altered PK when studying a microdose. 15 A very elegant approach to study dose linearity is by comparing the PK parameters of an isolated [ 14 C]microdose with the PK parameters of a [ 14 C]microtracer, where the labelled microdose is administered concurrently or even mixed with a therapeutic drug dose. 12 Cytochrome P450 (CYP) 3A is a developmentally regulated drug metabolizing enzyme that is abundant in the liver and accounts for nearly 46% of the oxidative metabolism of clinically relevant drugs. 1, 2, [16] [17] [18] [19] [20] [21] As midazolam is a well-established model substrate for CYP3A activity, this drug may be used for phenotyping studies using a microdosing approach to elucidate developmental changes in CYP3A. 5, [22] [23] [24] [25] To the best of our knowledge, dose linearity of the PK of a microdose to those of a therapeutic dose of midazolam has been established in adults, 14, 26, 27 but not in children. However, the results in adults cannot simply be extrapolated to children due to the development of drug metabolism, hepatic blood flow, protein binding and drug transport.
We therefore aimed to study the dose linearity of the PK of a 
| Subjects
Children were eligible to be included in this study from birth up to age 2 years, when they had intravenous lines in place for intravenous administration, and had suitable vascular access for blood sampling. for blood sampling were based on the PK of midazolam in paediatric ICU patients where a median half-life of 5.5 hours was found. 28 To ensure complete sampling of a single dose, at least 5 times the half-life was taken. Moreover, to capture the distribution, metabolism and elimination phases, the sampling times were set at predose, and 0.17, 0.5, 1, 2, 4, 6, 10, 24 and 36 hours post-IV dose. The maximum number of study specific blood samples was limited to 6 per subject.
The specific time points for each patient were decided based on discussion between the research team, clinical team and parents to ensure cares were coordinated at this time and with minimal disruption to the patients' routine. The maximum amount of blood could not exceed the guidelines by European Medicines Agency (up to 1% of calculated circulating blood volume). 29 The blood samples were centrifuged and plasma was stored at −80°C until analysed. 
| Radiopharmaceutical preparation

| AMS analysis
[ 14 C] levels were quantified as described before. 13, 30 The ultraperformance liquid chromatography and AMS qualification were performed in accordance with the recommendation of the European Bioanalytical Forum. 31 The tin foil cups (see 2.5.1) were combusted on an elemental analyser (Vario Micro; Elementar, Langenselbold, Germany). Generated CO 2 was transferred to a home-built gas interface, composed of a zeolite trap and syringe. 30 Engineering Europe B.V., Amersfoort, The Netherlands) 32 was used.
The lower limit of quantification was 0.31 mBq mL −1 .
| Patient characteristics
Patient characteristics (age, weight) and patient laboratory values (creatinine, total bilirubin, ASAT, ALAT) were described using standard statistics, and data was presented as median (range and standard goodness of fit plots. For the OFV, a drop of more than 3.84 points between nested models was considered statistically significant, which corresponds to P < .05 assuming a χ 2 distribution. 34, 35 For the structural and error models, a decrease in OFV of 
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY, 37 and are permanently archived in the Concise Table 1 for the patient characteristics. There were no significant differences found between characteristics of the microdose and microtracer group.
The complete dataset included data on 67 blood samples. Eight measurements had [ 14 C]midazolam concentrations under the AMS detection limit and were not included in the analysis. 39 Inclusion of the covariate treatment (e.g. microtracer or microdose) upon inclusion on any of the PK parameters was found to not statistically significantly influence the model fit (ΔOFV >0.01).
| Exploration of the data
| Nonlinear mixed effects modelling
The PK parameter estimates of the final model and the bootstrap results are presented in Table 3 . 
| DISCUSSION
Our study shows dose linearity of the PK of a [ 14 Previously, studies have reported the midazolam PK in paediatrics after a single IV administration. [40] [41] [42] Clearance in our study was found to be 2.06 L h −1 for an infant of 4 kg (equal to 8.6 mL kg −1 min −1 ). In preterm infants, the clearance was reported to be lower (median 1.8
[range 0.7-6.7] mL kg −1 min −1 ) 40 reflecting that CYP3A activity is less mature in preterm infants than in an infant of 4 kg. A study with critically ill children reported a clearance of 1.11 L h −1 for an infant of 5 kg (equal to 3.7 mL kg −1 min −1 ), 43 which is lower than in our population.
This paper concludes that inflammation (reflected by high C-reactive protein concentrations) and/or number of failing organs influenced midazolam clearance, possibly as a result of reduced CYP3A activity. 43 The lower clearance can probably be explained by the fact that this study included patients with a higher inflammation-state and/or more failing organs, as subjects in the current study were only eligible when renal-or hepatic failure was absent. This is further evidenced by 2 studies investigating a 0.15 mg kg −1 dose in healthy children, where clearance was found to be similar (3-10 year old, clearance mean ± SD 9.11 ± 1.21 mL kg −1 min −1 ) 42 and slightly higher (0.5-2 year, clearance 11.3 ± 6.3 mL kg −1 min −1 ) 41 than in our population.
Regulatory authorities have indicated that microdose studies with radioactive labelled compounds are an acceptable component of drug development. 7, 44 However, to the best of our knowledge, this approach has not been used during paediatric drug development, despite this study and previous other studies illustrating feasibility and ethical acceptance in that population. [11] [12] [13] For paracetamol, the dose linearity of an oral and IV microdose was successfully assessed in paediatrics. 12 A slightly different approach was taken to study developmental changes in oral disposition of paracetamol and istered together with a therapeutic dose of IV paracetamol. 11, 13 The known developmental change from mainly sulfation to glucuronidation was confirmed, and data were added on intestinal and hepatic metabolism of paracetamol in a large paediatric age range.
Together with our study, these studies pave the way for microdose studies to be incorporated into paediatric drug development plans to explore PK in this vulnerable population.
This study is limited by the lack of information on the severity of disease and inflammation in these patients and by the wide age range in which extensive development in drug metabolism and transport occurs. The effect of age and disease on CYP3A activity increased the variability in PK of midazolam, possibly obscuring a difference between the PK of a microtracer and a microdose. However, we showed that the age range was comparable in both treatment groups, and we assumed the disease severity was similar in the 2 groups.
Another limitation is that the sample size is relatively small. Nevertheless, PK parameters between a microdose and a microtracer were similar and compared with literature values. Moreover, in adults, low sample sizes were used to show dose linearity of midazolam. 14 A future perspective more specific to this particular study is that the results indicate that a [ 14 C]midazolam microdose can be used as an alternative to a midazolam therapeutic dose to study CYP3A activity in children. In the case of taking that approach, an attempt can be made in extrapolating the results to other CYP3A-substrates and predict their disposition using a physiologically based pharmacokinetic modelling approach. Importantly, whether this may be possible will depend on the characteristics of these substrates, as described by Calvier et al. 45 As a substantial number of clinically relevant drugs used in children are metabolized by CYP3A, 16 this has the potential to impact the efficacy and safety of drug dosing in paediatrics through more informed adaptations of dosing regimens to this population.
We conclude that the PK parameters of [ 14 C]midazolam administered as a microdose did not differ significantly in young infants from that of a microtracer. This supports the dose linearity of an IV [ 14 
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